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Preeclampsia (PE) is defined as a hypertensive and coagulative disorder affecting about
2–8% of all pregnancies and is one of the main causes of maternal and fetal morbid-
ity and mortality. Despite the great amount of studies run in this field, little is known
about the precise pathogenic mechanisms behind PE. While endothelial and trophoblast
dysfunctions, exaggerated inflammatory response, and hypercoagulative state have been
shown to play a key role in the occurrence of PE, the primary trigger is still unknown. One
of the hypotheses is that some infectious agents may represent a trigger for PE onset.
Consistently, higher seroprevalence of Helicobacter pylori (HP) infection, a Gram-negative
bacterium with a specific tropism for human gastric mucosa, has been shown in women
with PE. Even tighter association has been found between PE and infection with cytotoxin-
associated gene-A (CagA)-positive strains of HP. Recent in vitro studies have shown that
anti-CagA antibodies cross-react with human trophoblast cells and determine a functional
impairment in terms of cell invasiveness, thus, providing the first pathogenic model of
HP infection-mediated placental damage. Since in the early process of implantation and
placental development, trophoblast invasion of maternal decidua is a crucial step, the pro-
posed autoimmune mechanism induced by HP infection, negatively interfering with the
fetal side of the early developing placenta, may represent a mechanism explaining the
higher seropositivity for HP infection among PE women. However, the contribution of HP
infection to the pathogenesis of PE or to the worsening of its clinical presentation need
to be further investigated as well as the possible impact of pre-pregnancy screening and
eradication of HP infection on the incidence of the syndrome.
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INTRODUCTION
Pre eclampsia (PE) is generally defined as new hypertension and
substantial proteinuria at or after 20 weeks’ gestation (1). Com-
plicating 2–8% of pregnancies, PE is a major cause of severe
maternal morbidity and mortality and adverse perinatal outcomes
worldwide (2, 3).
In the last 20 years, the incidence of PE has risen in the Western
Countries, probably due to an increased prevalence of predispos-
ing factors, such as advanced maternal age, chronic hypertension,
diabetes, obesity, and the growing use of assisted reproductive
techniques (4, 5).
Despite the great socio-economic impact of PE and the amount
of studies carried out in this field, the pathogenic mechanisms
leading to PE onset still remains unclear as well as an effective
preventive intervention is still lacking (6).
The placental origins of PE have long been recognized and
then formalized in the two stage model of the syndrome (7).
The first stage is represented by inadequate development of the
early placenta and its maternal blood supply, called poor pla-
centation, which is established before 20 weeks and before clin-
ical signs appear. During physiological placental development,
extensive remodeling of maternal spiral arteries takes place in
order to supply increased need of maternal blood in the second
two trimesters of pregnancy. That process depends on extravil-
lous cytotrophoblasts that invade the lining of the pregnant uterus
from weeks 6 to 18 of gestation, expanding the vascular capacity
of the utero-placental circulation (8). In many cases of PE, tro-
phoblast invasion has been shown to be inadequate with poorly
remodeled arteries and reduced capacity of the utero-placental
circulation (9).
In the second stage, a dysfunctional and hypoxic placenta is
considered to release factors into the maternal circulation that
cause the clinical features of this condition, including hyperten-
sion and proteinuria, as well as clotting and liver dysfunction.
These appear to arise from a generalized systemic inflamma-
tory response, of which endothelial dysfunction is a prominent
component (7).
Thus, nowadays, one of the biggest challenges in the research
field of PE is to identify possible primary triggers of poor placen-
tation, then leading to clinical PE, in order to develop effective
preventative interventions. In that scenario, a possible role for
infections has been widely suggested.
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EPIDEMIOLOGIC ASSOCIATION BETWEEN HELICOBACTER
PYLORI INFECTION AND PREECLAMPSIA
In the last few years, an epidemiological link between Helicobacter
pylori (HP) infection and PE has been observed (10–13).
Helicobacter pylori is a Gram-negative bacterium with a spe-
cific tropism for the gastric mucosa (14); it is the main cause of
chronic gastritis and peptic ulcer, as well as a risk factor for MALT-
lymphoma and gastric cancer (15). Only some strains of HP pos-
sess determinants of pathogenicity, able to modulate the local and
systemic inflammatory response (16), like the cytotoxin-associated
gene-A (CagA), which encodes for a hydrophilic, surface-exposed
protein (17). CagA-positive strains of HP have been shown to
induce an inflammatory response in the gastric mucosa greater
than that induced by CagA-negative ones (18). Owing to its
capability to stimulate the immune system, HP has also been pro-
posed to play a role in some extra-gastric diseases; in particular,
the epidemiological association between HP infection and vascu-
lar diseases has been shown, including ischemic heart diseases,
primary Raynaud’s phenomenon and migraine, all conditions
characterized by endothelial dysfunction (19, 20).
Interestingly, anti-CagA antibodies seem to be able to cross-
react with antigens localized on the surface of human endothelial
cells in either normal or atherosclerotic arteries, thus providing a
possible mechanism explaining this association (21, 22).
Daví and co-authors have shown an association between HP
infection and high levels of in vivo markers of lipid peroxida-
tion and platelet activation, urinary 8-iso-PGF2 and 11-dehydro-
TXB2, respectively. Interestingly, successful eradication of HP
infection led to a significant reduction in both markers, suggesting
a novel mechanism by which an infectious agent could contribute
to atherothrombosis (23).
A few years ago, Ponzetto et al. showed, for the first time, higher
seropositivity for HP infection in 47 mothers with PE (51.1%)
compared with 47 women with uneventful pregnancy (31.9%).
The difference was even greater when considering positivity for
CagA-positive strains of HP (80.9 and 14.9%, respectively) (10).
This epidemiologic association has subsequently been con-
firmed by several studies (11, 13) (Table 1), and a correlation
Table 1 | Studies investigating the prevalence of HP infection in
general, and CagA+ strains HP infection, in particular, in healthy
pregnant women (CTR) in comparison with preeclamptic women (PE).
Authors Population
(n)
HP+
(%)
P CagA+
(%)
P
Ponzetto et al. (10) CTR=47 31.9 14.9
PE=47 51.1 0.033 80.9 <0.001
UstUn et al. (11) CTR=40 12.5 – –
PE=40 35.0 0.034 – –
Pugliese et al. (12) CTR=25 32.0 28.0
PE=25 84.0 <0.001 80.0 <0.001
Cardaropoli et al. (13) CTR=49 42.9 22.4
PE=49 85.7 <0.001 81.6 <0.001
P<0.05: statistically significant.
between persistent and virulent infections (VacA/CagA seropos-
itive patients) for HP and PE complicated by fetal intrauterine
growth restriction (IUGR) has also been shown (13).
Thus, since the association between HP infection and PE
occurrence has been widely confirmed, we hypothesized that this
bacterial infection might have a role as possible trigger in the
etiopathogenesis of PE.
ANTI-CagA ANTIBODIES CLASS IgG-MEDIATED
TROPHOBLAST INVASION INHIBITION: AN IN VITRO MODEL
OF HP-INDUCED POOR PLACENTATION
To try to answer that question, we investigated whether HP infec-
tion might induce an immune humoral response able to trigger an
autoantibody-mediated placental cellular damage. In particular,
since anti-CagA antibodies are able to cross-react with antigens of
endothelial cells (21) and cytotrophoblast cells show an endothe-
lial origin, we tested murine anti-CagA antibodies class IgG – the
only class of immunoglobulins able to cross placental barrier on
human primary trophoblast cultures in order to find a possible
cross-reaction. Interestingly, we observed that anti-CagA antibod-
ies are able to bind, on the surface of trophoblast cells, to β-actin
protein, one of the main components of cell cytoskeleton (24).
Consistently, immunofluorescence performed on trophoblast cells
using either anti-CagA or anti-β-actin antibodies showed an iden-
tical pattern of reaction, thus confirming β-actin to be the real
cross-reacting protein. Interestingly, actin, in either endothelial or
trophoblast cells, is not only important for maintaining the cell
structure but it is also crucial for intercellular adhesion (25, 26)
and it is now well established that actin-associated adhesions con-
tribute to placental anchorage (26). We observed that anti-CagA
antibodies show a dose-dependent binding activity as well and, as
biological effect, a dose-dependent impairment of cytotrophoblast
invasiveness in vitro, a crucial point for PE development. Further-
more, to better understand the molecular mechanisms involved in
the antibody-mediated functional impairment of trophoblast cells,
we examined the effect of anti-CagA on ERK activation and NF-kB
nuclear translocation, two important factors activated during tro-
phoblast proliferation, and we observed that anti-CagA antibodies
are able to inhibit the activation of both elements (24).
As a whole, these observations provided a possible autoimmune
pathogenic mechanism induced by HP infection, negatively inter-
fering with the fetal side of placental development. This pathogenic
model of autoimmune-mediated placental impairment is the first
one linking HP infection, poor placentation, and PE (Figure 1).
DISCUSSION
Although the cause of PE remains largely unknown, the leading
hypotheses strongly rely on disturbed placental function early in
pregnancy (27). Impaired remodeling of the spiral arteries has
especially been considered as an early defect causing PE (28).
Inadequate placentation may lead to impaired intervillous per-
fusion and to the establishment of placental hypoxic status, causing
oxidative stress of trophoblast cells and the release in mater-
nal circulation of anti-angiogenic factors and trophoblast debris,
believed to mediate maternal systemic inflammatory response,
endothelial dysfunction, and hypercoagulability in PE syndrome
(28, 29).
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FIGURE 1 | Supposed mechanism of Helicobacter pylori
infection-induced molecular mimicry leading to cross-reaction of
anti-CagA antibodies to trophoblast cells and poor placentation.
Several studies suggested a strong association between PE and
HP infections (10–13). Our in vitro studies showed an anti-CagA
antibody-mediated mechanism of placental impairment at fetal
side of early placental development. Thus, it is likely that anti-
bodies directed against bacterial CagA protein might cross-react
with antigens expressed on trophoblast cell, and in particular with
β-actin, through an immunologic mechanism called molecular
mimicry, leading to autoimmune response. This binding could
inhibit significantly trophoblast invasiveness, probably negatively
interfering with intracellular signaling ad intercellular connec-
tions, potentially leading to inadequate placental development.
That could represent an intriguing model of infection-induced
autoimmune triggering for poor placentation and PE onset, giv-
ing an explanation to the higher prevalence of HP infection among
women developing PE.
CONCLUSION
More studies are needed to further investigate the impact of HP
infection in triggering PE onset or, eventually, in worsening its
clinical presentation.
However, it should be considered that, nowadays, in obstetrical
practice, diseases with lower incidence than PE, like Rh alloimmu-
nization or Down’s syndrome, are commonly screened. Thus, if
HP will be confirmed as a contributing factor to PE, it will have
important positive implications for the public health system, since
the infection is treatable, and the future challenge would be to
assess whether pre-pregnancy screening and preventive HP eradi-
cation would reduce the incidence of PE or moderate the severity
of its clinical presentation.
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